Invivyd Inc. is a biopharmaceutical company dedicated to delivering protection from serious viral infectious diseases through innovative antibody-based therapies. It employs a proprietary integrated technology platform that combines state-of-the-art viral surveillance, predictive modeling, and advanced antibody engineering to develop potent monoclonal antibodies more resistant to virus evolution than the natural human immune system. The company focuses on a robust pipeline of product candidates for prevention and treatment of high-need indications, starting with COVID-19—such as pemivibart, an extended-half-life monoclonal antibody authorized for pre-exposure prophylaxis—and expanding into influenza and other viral threats. Invivyd Inc. supports patients through programs offering benefits investigations, access and reimbursement assistance, treatment coordination, and payor advocacy. It also pursues research and development collaborations with academic institutions, medical centers, and biopharma partners to advance antibody discovery and engineering. With expertise in monoclonal antibody development, clinical trial management, and regulatory affairs for biologics, Invivyd Inc. aims to protect vulnerable populations from evolving viral threats. Headquartered in Waltham, Massachusetts, the company operates from facilities in New Haven, Connecticut.